Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM Extension: Long-term denosumab in postmenopausal osteoporosis
NCT00523341Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2007
- Primary completion
- Jul 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in osteoporosis, sponsored by Amgen. Started Aug 2007; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00523341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523341.